Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Published in Science, a ground-breaking study by the Slack group reveals how combining vaccines with friendly bacteria can boost vaccination efficacy and potentially reduce reliance on antibiotics.

Black and white picture of intestinal pathogens
The international collaboration between Professor Emma Slack, from the Dunn School and the ETH Zurich, and Professor Médéric Diard  from the Biozentrum at the University of Basel, has developed a game-changing approach to combat harmful intestinal bacteria. Their research, conducted in mice, shows that combining oral vaccines with harmless bacteria is a highly effective approach to improving vaccine efficacy. The harmless bacteria outcompete the pathogenic bacteria for nutrients in the intestine, working in synergy with the vaccine to eliminate pathogenic bacteria more effectively than vaccination or treatment with harmless bacteria alone.

This combined approach not only prevented Salmonella infection in mice, but also eliminated established pathogenic E.coli infections. For this approach to work, the harmless bacteria must be able to thrive in the same environment as the pathogenic bacteria, with similar nutrient, oxygen and acidity requirements. The researchers used genetic engineering to develop a competitive harmless bacteria strain, though naturally selected E. coli strains were also effective.

“Although we can decimate pathogenic bacteria with a vaccine, we need harmless microorganisms to fill the resulting niche in the intestinal ecosystem in order to achieve long-term success,” explained Professor Slack. “It’s like gardening. If you want to avoid weeds in an area of the garden, you must plant other plants there after weeding. If you leave the soil empty, the weeds will just grow back.”

 

Read the full story on the Sir William Dunn School of Pathology website.

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience